Drug
MT 1186
MT 1186: highest development phase Phase 3, developed by Shionogi. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| MT-1186 NCT05151471 | Phase 3 | ALS |
| MT-1186 NCT04569084 | Phase 3 | ALS |
| MT-1186 NCT05342597 | Phase 1 | Healthy Adult Subjects |
| MT-1186 NCT04176224 | Phase 1 | Japanese Patients With ALS |
Latest
No recent events.
Follow MT 1186 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.